Chronic obstructive pulmonary disease and cardiovascular diseases;Przewlekła obturacyjna choroba płuc a choroby układu sercowo-naczyniowego

Pneumonologia i Alergologia Polska

Volumn 78, Issue 1, 2010, Pages 28-32

  Passowicz Muszyńska, Ewa ^a   Gostkowska Malec, Anna ^a   Jankowska, Renata ^a   Piesiak, Paweł ^a  

^a Katedra i Klinika Pulmonologii i Nowotworów   (Poland)

Author keywords

Atherosclerosis; Chronic obstructive pulmonary disease; Inflammation

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE COURSE; HOSPITALIZATION; HUMAN; POLAND; REVIEW; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMORBIDITY; CORONARY DISEASE; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POLAND; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77950473939     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Bednarek M., Maciejewski J., Woźniak M., Kuca P., Zieliński J. Chronic obstructive pulmonary disease. Prevalance, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008; 63: 402-407.
2. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2008). www.goldcopd.org/.
3. Chatila W.M., Thomashow B.M., Minai O.A., Criner G.J., Make B.J. Comorbidities in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2008; 5: 549-555.
4. Sin D.D., Wu L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952-1959.
5. Mills N.L., Miller J.J., Anand A., i wsp. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008; 63: 306-311.
6. Maclay J.D., McAllister D.A., MacNee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology 2007; 12: 634-641.
7. McAllister D.A., Maclay J.D., Mills N.L., i wsp. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 176: 1208-1214.
8. Shifren A., Mecham R.P. The stumbling block in lung repair of emphysema: elastic fiber assembly. Proc. Am. Thorac. Soc. 2006; 3: 428-433.
9. Makita H., Nasuhara Y., Betsuyaku T., Onodera Y., Hizawa N., Nishimura M. Characterization of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007; 62: 932-937.
10. Guerassimov A., Hoshino Y., Takubo Y., i wsp. The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am. J. Respir. Crit. Care Med. 2004; 170: 974-980.
11. Pyeritz R.E. The Marfan syndrome. Annu. Rev. Med. 2000; 51: 481-510.
12. Patel B.D., Loo W.J., Tasker A.D., i wsp. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax 2006; 61: 568-671.
13. Gan W.Q., Man S.F., Senthilselvan A.S., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax 2004; 59: 574-580.
14. Wedzicha J.A., Seemungal T.A., MacCallum P.K., i wsp. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb. Haemost. 2000; 84: 210-215.
15. Sin D.D., Lacy P., York E., Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 760-765.
16. Joppa P., Petrasova D., Stancak B., Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006; 130: 326-333.
17. Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 2003; 22: 809-814.
18. Engstrom G., Wollmer P., Hedblad B., Juul-Moller S., Valind S., Janzon L. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from"men born in 1914" Malmo, Sweden. Circulation 2001; 103: 3086-3091.
19. Sin D.D., Man S.F. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2005; 2: 8-11.
20. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am. J. Respir. Crit. Care Med. 2002; 166: 333-339.
21. Mapel D.W., Dedrick D., Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration medical system, 1991-1999. COPD 2005; 2: 35-41.
22. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-126.
23. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
24. De Reuck J., Proot P., Van Maele G. Chronic obstructive pulmonary disease as a risk factor for stroke-related seizures. Eur. J. Neurol. 2007; 14: 989-992.
25. Arboix J., Morcillo C., Garcia-Eroles L., Oliveres M., Massons J., Targa C. Different vascular risk factor profiles in ischemic stroke subtypes: a study from the "Sagrat Cor Hospital of Barcelona Stroke Registry". Acta Neurol. Scand. 2000; 102: 264-270.
26. Buch P., Friberg J., Scharling H., Lange P., Prescott E. Reduced lung function and the risk of atrial fibrillation in the Copenhagen City Heart Study. Eur. Respir. J. 2003; 21: 1012-1016.
27. Huerta C., Lanes S.F., Garcia Rodriguez L.A. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005; 16: 360-366.
28. Salpeter S., Ormiston T., Salpeter E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125: 2309-2321.
29. Calverley P.M., Anderson J.A., Celli B., i wsp. TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789.
30. Luppi F., Franco F., Beghé B., Fabbri L.M. Treatment of chronic obstructive pulmonary disease and its comorbidites. Proc. Am. Thorac. Soc. 2008; 5: 848-856.
31. Barnes P.J. Future treatments for chronic obstructive pulmonary disease and its comorbidites. Proc. Am. Thorac. Soc. 2008; 5: 857-864.
32. Dobler C.C., Wong K.K., Marks G.B. Associations between statins and COPD: a systematic review. BMC Pulm. Med. 2009; 9: 32-37.
33. Mancini G.B., Etminan M., Zhang B., Levesque L.E., FitzGerald J.M., Brophy J.M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006; 47: 2554-2560.
34. Soyseth V., Brekke P.H., Smith P., Omland T. Statin use is associated with reduced mortality in COPD. Eur. Respir. J. 2007; 29: 279-283.
35. Ridker P.M. JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108: 2292-2297.
36. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in Creactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-1193.
37. Mortensen E.M., Copeland L.A., Pugh M.J., i wsp. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir. Res. 2009; 10: 45-53.
38. Kim S.E., Thanh Thuy T.T., Lee J.H., i wsp. Simvastatin inhibits induction of matrix metalloproteinase - 9 in rat alveolar macrophages exposed to cigarette smoke extract. Exp. Mol. Med. 2009; 41: 277-287.
39. Nissen S.E., Nicholls S.J., Sipahi I., i wsp. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the asteroid trial. JAMA 2006; 295: 1556-1565.
40. Nicholls S.J., Tuzcu E.M., Sipahi I., i wsp. Statins high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508.
41. Turato G., Di Stefano A., Maestrelli P., i wsp. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am. J. Respir. Crit. Care Med. 1995; 152: 1262-1267.
42. Alexeff S.E., Litonjua A.A., Sparrow D., Vokonas P.S., Schwartz J. Statin use reduces decline in lung function: VA normative aging study. Am. J. Respir. Crit. Care Med. 2007; 176: 742-747.
43. Khurana V., Bejjanki H.R., Caldito G., Owens M.W. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007; 131: 1282-1288.